Element Materials Technology to Expand its North American Presence with Avomeen Acquisition
Through the acquisition, Element will have access to Avomeen’s expertise in formulation chemistry, product manufacturing, extractables and leachables, and large molecule testing.
Element Materials Technology, a UK-based testing, inspection, and certification services company, announced on Feb. 3, 2021 that is acquiring Avomeen, an analytical testing services company located in the US, to expand its life sciences business unit in North America.
Through the acquisition, Element will have access to Avomeen’s expertise in formulation chemistry, product manufacturing, extractables and leachables, and large molecule testing, thus strengthening its technical range across several scientific disciplines, Element said in a company press release.
“We are thrilled to be joining the Element global family and combining our complementary capabilities to offer an even wider array of services and value to our clients,” said Mark Harvill, Avomeen CEO, in the press release. “Element’s focus on scientific excellence and quality, coupled with its partnership with clients and employees, aligns well with Avomeen’s values and what we will collectively continue to do as one company.”
“This is our third acquisition of 2021 and helps to build Element’s growing position in the life sciences sector, expanding our presence in the American pharmaceutical market,” added Jo Wetz, Element CEO, in the press release.
Source: Element
Novartis Acquisition of Regulus Therapeutics is Complete
June 25th 2025A key property included in the acquisition is farabursen, an investigational next-generation oligonucleotide targeting the microRNA miR-17 with preferential kidney exposure, intended to treat people with autosomal dominant polycystic kidney disease.
VERAXA and Voyager to Create Combined Business for Advancing Pipeline of Next-Gen Cancer Therapies
April 23rd 2025The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company that will focus on developing a pipeline of next-generation cancer therapies.
